LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/AI Software Firm for Ortho Manufacturers Raises Capital
Company News

AI Software Firm for Ortho Manufacturers Raises Capital

July 6, 2021 2 min read Premium comments

Advertisement

Secondary#enhatch#aienabledsoftware

Hoboken, New Jersey-based Enhatch Inc., a provider of a cloud-based intelligent surgery platform, has just closed on a funding round from software growth equity firms Trousdale Capital and Apis Holdings, with participation by Enhatch’s existing major investors. Enhatch has doubled its staff since the investment.

Enhatch’s Intelligent Surgery platform is aimed at manufacturers and suppliers of medical devices.

The funds will be used, said Peter Verrillo, Enhatch CEO, to “Integrate Intelligent Surgery into every aspect of the medical device industry and to ensure our partners have an enterprise-level customer experience.

Enhatch’s intelligent platform provides, said Verrillo, “A robust, end-to-end solution that allows companies to remain competitive no matter their size or balance sheet, surgeons to work more efficiently, and procedures to become more accurate.”

“We are delivering artificial intelligence to level the playing field; allowing any startup, small or midsize device company to leverage an enterprise platform more powerful than the largest device companies in the world.”

“Recent breakthroughs in artificial intelligence, surgical robotics, and 3D printing are revolutionizing surgeries in the same way advents such as laparoscopy transformed surgeries in the 20th century”, says Nima Shahian, founder and managing partner of Trousdale Capital, and recently appointed member of Enhatch’s board of directors. “We’re excited to partner with Enhatch in disrupting the surgical supply chain to deliver cost savings, surgical optimization, and enterprise efficiency to medical device companies, surgeons, and patients.”

“In partnership with the broader community, we continue to make significant investments in talent and quality of life here in Tulsa,” says Jay Calhoun, managing partner of Apis Holdings and chairman of Enhatch’s board of directors. “We think these strategic investments directly benefit technology, data, and service companies like Enhatch, who are seeking long-term partners who can help grow their operations to enterprise scale. We’ve been able to respond quickly to Enhatch’s aggressive hiring needs, pulling together a powerful combination of top-notch talent and friendly, customer-oriented team members. We do this while collaborating with management to build an enduring company with strong unit economics.”

When OTW asked what specific inefficiencies they are targeting, Peter Verrillo commented, “There is a lot of human power involved with doing preoperative planned surgeries, logistics of hundreds of instruments, and even during surgery. The latest robot/nav[igation] solutions take longer than an efficiently run traditional instrumented surgery.”

Advertisement

Looking forward, as the calendar hits the one-year mark, said Verrillo to OTW, they will have performed the initial Intelligent Surgeries and have early clinical data.

“There is an underlying problem in the device industry that causes billions in unnecessary logistics expenses,” added Verrillo. We have seen it plague many of our customers through the years, as you scale from $1 to $10 to $100M[illion] in revenue, device companies do not have access to the capital necessary for scaling and supporting surgical cases. Enhatch and Intelligent Surgery gives every company the ability to scale and grow economically.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy